Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides

Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute live...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 822154
Main Authors Shi, Qiaoli, Wang, Qixin, Chen, Jiayun, Xia, Fei, Qiu, Chong, Li, Min, Zhao, Minghong, Zhang, Qian, Luo, Piao, Lu, Tianming, Zhang, Ying, Xu, Liting, He, Xueling, Zhong, Tianyu, Lin, Na, Guo, Qiuyan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro . Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro . Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.
AbstractList Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated.Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites.Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation.Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro.Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity.Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.
Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro . Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin–eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro . Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.
Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. TGT-induced acute liver injury models were constructed and . Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both and . Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.
Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro. Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet (TGT)-induced acute liver injury remain unelucidated. Hypothesis/Purpose: We assumed that GA could relieve TGT-induced acute liver injury by regulating liver function-related genes and lipid metabolites. Study Design: TGT-induced acute liver injury models were constructed in vivo and in vitro. Then the liver protective effect and mechanisms of GA were investigated by a combination of transcriptome, lipid metabolomics, and experimental validation. Methods: Intraperitoneal injection of GA was given in advance for six successive days. Then, the TGT-induced acute liver injury model was constructed by a single oral administration of TGT at 270 mg/kg, except for the normal group. All animals were sacrificed 18 h later. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutathione peroxidase (GSH-PX), and superoxide dismutase (SOD) were quantified. Liver tissues were used to observe pathological changes through hematoxylin-eosin (HE) staining and selected for transcriptome and metabolome sequencing. The underlying mechanisms were analyzed and further validated both in vivo and in vitro. Results: Pre-administration of GA markedly decreased the serum concentrations of AST, ALT, ALP, and TBIL but increased those of SOD and GSH-Px, improving the liver morphology of mice with TGT-induced acute liver injury. In addition, GA significantly increased the gene levels of Cyp2b13, Cyp2c69, Cyp3a16, Cyp3a44, Fmo3, and Nipal1. Differentially accumulated metabolites were screened and classified as phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The in vitro results indicated that pre-administration of GA markedly alleviated the inhibitory effect of TGT on BRL-3A activity. Conclusion: This study combined transcriptome, lipid metabolomics, and experimental validation to offer convincing evidence that GA alleviates TGT-induced acute liver injury partially by regulating the activities of CYP and the metabolism of PC and PE.
Author Guo, Qiuyan
Li, Min
Zhang, Qian
He, Xueling
Chen, Jiayun
Luo, Piao
Wang, Qixin
Zhong, Tianyu
Xia, Fei
Zhao, Minghong
Lin, Na
Xu, Liting
Qiu, Chong
Zhang, Ying
Lu, Tianming
Shi, Qiaoli
AuthorAffiliation 4 Laboratory Medicine , First Affiliated Hospital of Gannan Medical University , Ganzhou , China
2 China Academy of Chinese Medical Sciences , Beijing , China
3 Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases , Ministry of Education , Gannan Medical University , Ganzhou , China
1 Artemisinin Research Center and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing , China
AuthorAffiliation_xml – name: 2 China Academy of Chinese Medical Sciences , Beijing , China
– name: 3 Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases , Ministry of Education , Gannan Medical University , Ganzhou , China
– name: 1 Artemisinin Research Center and Institute of Chinese Materia Medica , China Academy of Chinese Medical Sciences , Beijing , China
– name: 4 Laboratory Medicine , First Affiliated Hospital of Gannan Medical University , Ganzhou , China
Author_xml – sequence: 1
  givenname: Qiaoli
  surname: Shi
  fullname: Shi, Qiaoli
– sequence: 2
  givenname: Qixin
  surname: Wang
  fullname: Wang, Qixin
– sequence: 3
  givenname: Jiayun
  surname: Chen
  fullname: Chen, Jiayun
– sequence: 4
  givenname: Fei
  surname: Xia
  fullname: Xia, Fei
– sequence: 5
  givenname: Chong
  surname: Qiu
  fullname: Qiu, Chong
– sequence: 6
  givenname: Min
  surname: Li
  fullname: Li, Min
– sequence: 7
  givenname: Minghong
  surname: Zhao
  fullname: Zhao, Minghong
– sequence: 8
  givenname: Qian
  surname: Zhang
  fullname: Zhang, Qian
– sequence: 9
  givenname: Piao
  surname: Luo
  fullname: Luo, Piao
– sequence: 10
  givenname: Tianming
  surname: Lu
  fullname: Lu, Tianming
– sequence: 11
  givenname: Ying
  surname: Zhang
  fullname: Zhang, Ying
– sequence: 12
  givenname: Liting
  surname: Xu
  fullname: Xu, Liting
– sequence: 13
  givenname: Xueling
  surname: He
  fullname: He, Xueling
– sequence: 14
  givenname: Tianyu
  surname: Zhong
  fullname: Zhong, Tianyu
– sequence: 15
  givenname: Na
  surname: Lin
  fullname: Lin, Na
– sequence: 16
  givenname: Qiuyan
  surname: Guo
  fullname: Guo, Qiuyan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35237151$$D View this record in MEDLINE/PubMed
BookMark eNp1ks2O0zAUhSM0iBmGeQA2yEs2KfFPEocFUikwVCpihMqCleXYTurKiYPtVAovyuvgtB00g4QXdpR77neu7PM8uehtr5LkJcwWGNPqTTPsuFugDMEFRQjm5ElyBYsCpxWF6OLB92Vy4_0-iwtXFS7Is-QS5wiXMIdXye-t470XTg_BdgrwXoKNHrQEX1TgtTW208Kn77lXEnzQXtiDctNbcGsmMTm307-0AEsR9Utj1EHzoDzYzrQoa_XYHZXWa6nAltdGhXTdy1FE2lKMQUWzCATrfj-6CdQT-Kba0fCg-xaEnYqioA866Ei1DVj9uDtOOFfO82nfzZW7nfXDzrbRTLlo5l8kTxtuvLo5n9fJ908ft6vP6ebr7Xq13KSCFHlIC04oFRgKnMcb5KjJSUUaAgUsc44Rl4oTomouGiwJxVJVJS3LClUZwVgWCF8n6xNXWr5ng9MddxOzXLPjD-taxl3QwiiWo0piQeqmrCqCKeFFgyFqZMQVcaOR9e7EGsa6U1KoPjhuHkEfV3q9Y609MEopjvNEwOszwNmfo_KBdfHJlDG8V3b0DBU4JzSrSBalrx56_TW5T0YUlCeBcNZ7pxomdIgPY2drbRjM2BxDdowhm2PITjGMnfCfznv4_3v-AJtp5fA
CitedBy_id crossref_primary_10_1002_efd2_70028
crossref_primary_10_1186_s40360_024_00732_y
crossref_primary_10_1186_s43066_023_00248_w
crossref_primary_10_1016_j_jpha_2023_03_004
crossref_primary_10_1093_toxres_tfae009
crossref_primary_10_1016_j_jff_2024_106390
crossref_primary_10_3390_metabo12111128
crossref_primary_10_3390_microorganisms12061155
crossref_primary_10_3389_fnut_2024_1370975
Cites_doi 10.1124/dmd.116.069419
10.1155/2021/6699560
10.1371/journal.pone.0089450
10.3969/j.issn.1001-5256.2019.08.006
10.1186/s12944-017-0540-4
10.1007/s11010-015-2523-y
10.1016/j.tox.2014.08.013
10.1016/j.phymed.2015.05.053
10.1007/s00216-016-9533-9
10.1016/j.tox.2017.05.012
10.3867/j.issn.1000-3002.2012.03.028
10.7501/j.issn.1674-6376.2017.10.030
10.3760/cma.j.issn.1008-1275.2014.01.001
10.1210/me.2004-0129
10.13193/j.issn.1673-7717.2021.05.017
10.1016/j.phymed.2012.10.013
10.19540/j.cnki.cjcmm.20200710.501
10.1016/j.pharmthera.2013.09.002
10.1007/s00109-011-0771-1
10.2147/DDDT.S220030
10.1016/j.phymed.2019.152855
10.1002/jat.2906
10.7539/j.issn.1672-2981.2017.03.017
10.16438/j.0513-4870.2017-0317
10.19540/j.cnki.cjcmm.20190527.408
10.3390/ijms150915026
10.3390/ijms161125942
10.3969/j.issn.1671-3141.2017.07.016
ContentType Journal Article
Copyright Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo.
Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo
Copyright_xml – notice: Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo.
– notice: Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo. 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2021.822154
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Shi et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_529d3c4bf7994384a6f312fd7926d798
PMC8883433
35237151
10_3389_fphar_2021_822154
Genre Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-6a488c31c35154a2f5494f41c175a32adea44ebacf3d483de978779290433d623
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:20:38 EDT 2025
Thu Aug 21 13:58:21 EDT 2025
Thu Jul 10 17:47:16 EDT 2025
Thu Jan 02 22:56:31 EST 2025
Tue Jul 01 03:27:52 EDT 2025
Thu Apr 24 23:02:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords tripterygium glycoside tablet
liver injury
lipid metabolomics
glycyrrhizic acid
transcriptome
Language English
License Copyright © 2022 Shi, Wang, Chen, Xia, Qiu, Li, Zhao, Zhang, Luo, Lu, Zhang, Xu, He, Zhong, Lin and Guo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-6a488c31c35154a2f5494f41c175a32adea44ebacf3d483de978779290433d623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Wang Lingzhi, National University of Singapore, Singapore
Jinfa Tang, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, China
Reviewed by: Chao Han, China Pharmaceutical University, China
These authors have contributed equally to this work and share first authorship
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2021.822154
PMID 35237151
PQID 2635480940
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_529d3c4bf7994384a6f312fd7926d798
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8883433
proquest_miscellaneous_2635480940
pubmed_primary_35237151
crossref_citationtrail_10_3389_fphar_2021_822154
crossref_primary_10_3389_fphar_2021_822154
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-14
PublicationDateYYYYMMDD 2022-02-14
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-14
  day: 14
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Ming (B15) 2017; 16
Wiwi (B23) 2004; 18
Tian (B21) 2019; 44
Liao (B12) 2012; 26
Stingl (B20) 2014; 141
Xie (B25) 2016; 408
Sil (B19) 2015; 409
Graeser (B5) 2011; 89
Ma (B14) 2017; 52
Richard (B17) 2021; 2021
Xia (B24) 2017; 17
Yan (B27) 2016; 44
Luo (B13) 2017; 40
Abuduxikuer (B1) 2019; 35
Gong (B4) 2014; 9
Gu (B6) 2014; 17
Wang (B22) 2017; 386
Kao (B10) 2013; 20
Hsiang (B8) 2015; 22
Na (B16) 2020; 45
Jiang (B9) 2021; 39
Gao (B3) 2019; 13
Xu (B26) 2017; 15
Hou (B7) 2014; 15
Du (B2) 2014; 34
Rudraiah (B18) 2014; 325
Yang (B28) 2019; 58
Li (B11) 2015; 16
References_xml – volume: 44
  start-page: 720
  year: 2016
  ident: B27
  article-title: Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor α-Mediated Apoptosis
  publication-title: Drug Metab. Dispos
  doi: 10.1124/dmd.116.069419
– volume: 2021
  start-page: 6699560
  year: 2021
  ident: B17
  article-title: Exploring the Pivotal Immunomodulatory and Anti-inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids
  publication-title: Mediators Inflamm.
  doi: 10.1155/2021/6699560
– volume: 9
  start-page: e89450
  year: 2014
  ident: B4
  article-title: Protective Effect of Glycyrrhizin, a Direct HMGB1 Inhibitor, on Focal Cerebral Ischemia/reperfusion-Induced Inflammation, Oxidative Stress, and Apoptosis in Rats
  publication-title: PloS one
  doi: 10.1371/journal.pone.0089450
– volume: 35
  start-page: 1684
  year: 2019
  ident: B1
  article-title: Congenital Disorders of Glycosylation and Liver Diseases
  publication-title: J. Clin. Hepatol. = lin chuang gan dan bing za zhi.
  doi: 10.3969/j.issn.1001-5256.2019.08.006
– volume: 16
  start-page: 153
  year: 2017
  ident: B15
  article-title: Liquid Chromatography Mass Spectrometry-Based Profiling of Phosphatidylcholine and Phosphatidylethanolamine in the Plasma and Liver of Acetaminophen-Induced Liver Injured Mice
  publication-title: Lipids Health Dis.
  doi: 10.1186/s12944-017-0540-4
– volume: 409
  start-page: 177
  year: 2015
  ident: B19
  article-title: Glycyrrhizin Ameliorates Metabolic Syndrome-Induced Liver Damage in Experimental Rat Model
  publication-title: Mol. Cell Biochem
  doi: 10.1007/s11010-015-2523-y
– volume: 325
  start-page: 85
  year: 2014
  ident: B18
  article-title: Differential Fmo3 Gene Expression in Various Liver Injury Models Involving Hepatic Oxidative Stress in Mice
  publication-title: Toxicology
  doi: 10.1016/j.tox.2014.08.013
– volume: 22
  start-page: 768
  year: 2015
  ident: B8
  article-title: Glycyrrhizin, Silymarin, and Ursodeoxycholic Acid Regulate a Common Hepatoprotective Pathway in HepG2 Cells
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2015.05.053
– volume: 408
  start-page: 4341
  year: 2016
  ident: B25
  article-title: Development and Application of a Comprehensive Lipidomic Analysis to Investigate Tripterygium Wilfordii-Induced Liver Injury
  publication-title: Anal. Bioanal. Chem.
  doi: 10.1007/s00216-016-9533-9
– volume: 386
  start-page: 133
  year: 2017
  ident: B22
  article-title: Glycyrrhizin and Glycyrrhetinic Acid Inhibits Alpha-Naphthyl Isothiocyanate-Induced Liver Injury and Bile Acid Cycle Disruption
  publication-title: Toxicology
  doi: 10.1016/j.tox.2017.05.012
– volume: 26
  start-page: 402
  year: 2012
  ident: B12
  article-title: Application Progress of Cytochrome Oxidase P450 Family in Toxicity Study of Traditional Chinese Medicine
  publication-title: Chin. J. Pharmacol. Toxicol. = zhong guo yao li xue yu du li xue za zhi.
  doi: 10.3867/j.issn.1000-3002.2012.03.028
– volume: 40
  start-page: 1504
  year: 2017
  ident: B13
  article-title: Research Progress of Hepatotoxicity Mechanism and Attenuation of Tripterygium Wilfordii Glycoside
  publication-title: Drug Eval. Res. = yao wu ping jia yan jiu.
  doi: 10.7501/j.issn.1674-6376.2017.10.030
– volume: 17
  start-page: 1
  year: 2014
  ident: B6
  article-title: Effect of Glycyrrhizin on Traumatic Brain Injury in Rats and its Mechanism
  publication-title: Chin. J. Traumatol.
  doi: 10.3760/cma.j.issn.1008-1275.2014.01.001
– volume: 18
  start-page: 1975
  year: 2004
  ident: B23
  article-title: Sexually Dimorphic P450 Gene Expression in Liver-specific Hepatocyte Nuclear Factor 4alpha-Deficient Mice
  publication-title: Mol. Endocrinol.
  doi: 10.1210/me.2004-0129
– volume: 39
  start-page: 64
  year: 2021
  ident: B9
  article-title: Research Progress on Adverse Reactions and Reducing Toxicity of Tripterygium Glycosides
  publication-title: Chin. rchives traditional Chin. Med. = zhong hua zhong yi yao xue kan.
  doi: 10.13193/j.issn.1673-7717.2021.05.017
– volume: 20
  start-page: 295
  year: 2013
  ident: B10
  article-title: Glycyrrhizic Acid and 18β-Glycyrrhetinic Acid Recover Glucocorticoid Resistance via PI3K-Induced AP1, CRE and NFAT Activation
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2012.10.013
– volume: 45
  start-page: 4149
  year: 2020
  ident: B16
  article-title: Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium Wilfordii Tablets in Treatment of Rheumatoid Arthritis
  publication-title: Zhongguo Zhong Yao Za Zhi
  doi: 10.19540/j.cnki.cjcmm.20200710.501
– volume: 141
  start-page: 92
  year: 2014
  ident: B20
  article-title: Relevance of UDP-Glucuronosyltransferase Polymorphisms for Drug Dosing: A Quantitative Systematic Review
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2013.09.002
– volume: 89
  start-page: 1027
  year: 2011
  ident: B5
  article-title: Nrf2-dependent Gene Expression Is Affected by the Proatherogenic apoE4 Genotype-Studies in Targeted Gene Replacement Mice
  publication-title: J. Mol. Med. (Berl)
  doi: 10.1007/s00109-011-0771-1
– volume: 13
  start-page: 3579
  year: 2019
  ident: B3
  article-title: Diammonium Glycyrrhizinate Mitigates Liver Injury via Inhibiting Proliferation of NKT Cells and Promoting Proliferation of Tregs
  publication-title: Drug Des. Devel Ther.
  doi: 10.2147/DDDT.S220030
– volume: 58
  start-page: 152855
  year: 2019
  ident: B28
  article-title: Tripterygium Glycoside Fraction N2: Alleviation of DSS-Induced Colitis by Modulating Immune Homeostasis in Mice
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2019.152855
– volume: 34
  start-page: 878
  year: 2014
  ident: B2
  article-title: Metabolic Pathways Leading to Detoxification of Triptolide, a Major Active Component of the Herbal Medicine Tripterygium Wilfordii
  publication-title: J. Appl. Toxicol.
  doi: 10.1002/jat.2906
– volume: 15
  start-page: 329
  year: 2017
  ident: B26
  article-title: Effect of Licorice on Drug Metabolism Enzymes and In Vivo Metabolism of Chemical Agents
  publication-title: Cent. south Pharm. = zhong nan yao xue
  doi: 10.7539/j.issn.1672-2981.2017.03.017
– volume: 52
  start-page: 1077
  year: 2017
  ident: B14
  article-title: Study of Metabolic Pathway of Radix glycyrrhiza in Decreasing Liver Toxicity of Tripterygium Wilfordii
  publication-title: Acta pharmaceutica sinica = yao xue xue bao
  doi: 10.16438/j.0513-4870.2017-0317
– volume: 44
  start-page: 3399
  year: 2019
  ident: B21
  article-title: Overview of Hepatotoxicity Studies on Tripterygium Wilfordii in Recent 20 Years
  publication-title: Zhongguo Zhong Yao Za Zhi
  doi: 10.19540/j.cnki.cjcmm.20190527.408
– volume: 15
  start-page: 15026
  year: 2014
  ident: B7
  article-title: The Protective Effect of Glycyrrhizic Acid on Renal Tubular Epithelial Cell Injury Induced by High Glucose
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms150915026
– volume: 16
  start-page: 26087
  year: 2015
  ident: B11
  article-title: The Role of Oxidative Stress and Antioxidants in Liver Diseases
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms161125942
– volume: 17
  start-page: 33
  year: 2017
  ident: B24
  article-title: Research Progress of Drug-Induced Liver Injury
  publication-title: World latest Med. Inf. = shi jie zui xin yi xue xin xi wen zhai
  doi: 10.3969/j.issn.1671-3141.2017.07.016
SSID ssj0000399364
Score 2.3868873
Snippet Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium...
Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium glycoside tablet...
Background: Glycyrrhizic acid (GA) has been reported to be liver protective; however, the characters and underlying mechanisms of GA against tripterygium...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 822154
SubjectTerms glycyrrhizic acid
lipid metabolomics
liver injury
Pharmacology
transcriptome
tripterygium glycoside tablet
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT70goHyEQjVIqAfUUBI7X71tC6UgFa3QViqnyLGdTdBustpkD-kf7d9hxkm3uwjBhcse1hPbip89bxTPG8beYmicoJcLXaORvoks13gOauWKhNTLDA-ykJKTL7-FF1fi63VwvVHqi-6E9fLA_Ys7DvxEc4WdREkieCxkmHPPz3WU-CH-2DRf9HkbwZQ9g8nvhqL_jIlRWHKcLwpJ-p--9x59oheILUdk9fr_RDJ_vyu54XzOH7GHA2uEUT_bx-yBqZ6ww3EvO90dweQ-i6o5gkMY3wtSd3vs1jokezzUcwOy0kAlqzVcmhYxMKPE5MY9RX-m4WPZKLrV2Z3A51mnuuWyKG9KBSOF9qMZJaMTO4UJ9YZm03I1t5Y11f2ECWVitS4VBFHY20itWoODYYfwpfqJ6wdZB9_N1BYNq6aA9BONbAULDNmhzuHsx9jOkFqG-ZXNnFrGRd0sinqKg-G20aZ5yq7OP03OLtyhoIOrRBi0bijxuFDcUxxZlJB-jsGpyIWnkMNI7kttpBAmkyrnWsRcGwxxI1zohFTWNBK1Z2ynqivzgoH2RBDLKMtwYYSKMykjjN106Ek_igI_cNiHu9VN1aB2TkU3ZilGPQSI1AIiJUCkPSAc9m79yKKX-vib8SlBZm1IKt32D8RuOmA3_Rd2HfbmDnAp7mr6VCMrU6-alCSCREzahg573gNwPRRSZh4hUXNYtAXNrblst1RlYZXD4zjm-Cpf_o_J77Ndn1JBqDiOeMV22uXKvEaC1mYHdi_-AsZHPgs
  priority: 102
  providerName: Directory of Open Access Journals
Title Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides
URI https://www.ncbi.nlm.nih.gov/pubmed/35237151
https://www.proquest.com/docview/2635480940
https://pubmed.ncbi.nlm.nih.gov/PMC8883433
https://doaj.org/article/529d3c4bf7994384a6f312fd7926d798
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRUJ7QbwJj5WR0B7QZiGx80JCqLuwLEhFFWql5RQ5tvNAbVKSVCL8Uf4OM07apajiwCWHePxoPOP5psl8Q8hzCI0j8HK-rRXAN56kCs5BJW0eIXuZZl7iY3Ly-LN_MeOfLr3LPbIubzU8wGZnaIf1pGb1_OTH9-4tGPwbjDjB375Ml7lAak_XOQF3B5jgGrkOjilAOx0PaN8czOiMfd6_29zd84DcAETCAsdzthyV4fPfBUL__pbyD-d0fovcHFAlHfVqcJvs6fIOOZr0tNTdMZ1eZVk1x_SITq4Iq7u75JdxWOb4qBaailJRLGmt6Fi3oCNzTFxu7FPwd4q-KxqJX312r-mHeSe7us6Ln4WkIwnyozkmqyN6pVMcDcSyYrUwkhXWBaVTzNRqbSwYImG0kVy1GiaDAenH8hvsL006-kVnpqhYmVGApyBkKlxASE-rlJ59nZgVYsuwvqJZYMskr5plXmUwGZiV0s09Mjt_Pz27sIeCD7bkvtfavoDjRDJHMkBZXLgpBK885Y4EjCOYK5QWnOtEyJQpHjKlIQQOAgB4yMKmAMjdJ_tlVeqHhCqHe6EIkgQ2hsswESKA2E75jnCDwHM9i7xa724sBzZ0LMoxjyEqQt2IjW7EqBtxrxsWebHpsuypQP4lfIoqsxFEFm9zo6qzeDgUYs-NFJNgIEEUcRZy4afMcVMFP8mHS2iRZ2uFi8Hq8VWOKHW1amKkEOIhch9a5EGvgJup1gpskWBLNbfWst1SFrlhFg_DkMGjfPTfPR-TAxfzQ7BiDn9C9tt6pZ8CamuTQ_Nvx6GxyN-XyEhp
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transcriptome+and+Lipid+Metabolomics-Based+Discovery%3A+Glycyrrhizic+Acid+Alleviates+Tripterygium+Glycoside+Tablet-Induced+Acute+Liver+Injury+by+Regulating+the+Activities+of+CYP+and+the+Metabolism+of+Phosphoglycerides&rft.jtitle=Frontiers+in+pharmacology&rft.au=Shi%2C+Qiaoli&rft.au=Wang%2C+Qixin&rft.au=Chen%2C+Jiayun&rft.au=Xia%2C+Fei&rft.date=2022-02-14&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.822154&rft_id=info%3Apmid%2F35237151&rft.externalDocID=PMC8883433
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon